The administration on control over products and medicines USA (FDA) was added to the list of drugs, the lack of which is experiencing the country’s healthcare industry, the antidepressant sertraline (the original drug was zoloft).
The Agency almost coincided with the publication of a study at Johns Hopkins University, which the authors noted a sharp increase in complaints of depression and a feeling of hopelessness among adult residents of the country.
The manufacturer of Zoloft, Pfizer declared that retains the ability to cover the current need for the drug, however, can hardly meet the growing demand. At the same time, FDA announces limited availability of the drug at doses of 50 and 100 mg.
Generic manufacturers of sertraline coming to the U.S. market are faced with interruptions in supplies of imported pharmaceutical substances, which are directly related to the consequences of quarantine measures.
In particular, the company Accord Healthcarе predicts a shortage of AFS for the production of this drug within the next 60 days. Pharmaceutical manufacturer Lupin also faced a shortage of AFS of sertraline as due to problems with imports, and increased demand for the drug. Assessment Lupin, the situation may take several months.
According to the company Ehre Scripts involved in drug supply within the framework of health insurance programs, the number of prescriptions for drugs for the treatment of depression, anxiety and insomnia in March 2020 rose 21% compared with the previous month.